All three compounds belong to the incretin-mimetic class of synthetic peptides — single-chain analogs modeled on the glucagon/secretin (glucagon-superfamily) peptide backbone and characterized as receptor agonists associated with metabolic and endocrinology research. Their principal distinction is receptor selectivity. Semaglutide is a mono-agonist directed at the GLP-1 (glucagon-like peptide-1) receptor. Tirzepatide is a dual agonist engineered to engage both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. Retatrutide extends this design further as a tri-agonist reported to act at the GIP, GLP-1, and glucagon receptors. In research nomenclature this represents a progression from single- to dual- to triple-receptor targeting within one structural family, and it is the central axis along which the three are compared analytically.
Structurally, each is a linear, chemically synthesized peptide rather than a recombinant protein, and all share the hallmark of lipidation: a fatty-diacid moiety conjugated to a lysine side chain through a spacer arrangement that includes a gamma-glutamate unit and short hydrophilic linkers. This acylation is a deliberate design feature reported to promote reversible binding to serum albumin in in-vitro and pharmacokinetic research systems, and it distinguishes these analogs from the shorter, non-acylated native incretin peptides. Semaglutide is the most compact of the three, comprising a 31-residue chain, whereas both tirzepatide and retatrutide are built on longer 39-residue backbones. Additional engineering common to the class includes substitution of non-coded amino acids such as alpha-aminoisobutyric acid (Aib) at positions prone to enzymatic cleavage, a modification associated in research assays with structural resistance to dipeptidyl peptidase-4 (DPP-4).
On the molecular-profile axis, the peptides differ chiefly in chain length and in the composition of their fatty-acid conjugates and residue substitutions, which in turn are reflected in their differing molecular weights (semaglutide being the lightest as the shortest chain, with the two 39-residue analogs being heavier). Because the compliance framework requires that no numeric molecular constants be invented, exact molecular formulas, monoisotopic masses, and CAS identifiers are intentionally omitted here where an authoritative provided value is absent; laboratories should confirm these constants against the certificate of analysis (CoA) and third-party analytical data accompanying a given research lot.
In physical format the three are handled almost identically for research use. Each is typically supplied as a sterile, lyophilized (freeze-dried) white-to-off-white powder sealed in a vial, requires reconstitution in a suitable aqueous diluent such as bacteriostatic or sterile water prior to in-vitro work, and is characterized by high aqueous solubility owing to its peptidic and hydrophilic-linker composition. Reconstituted solutions of all three are generally regarded as stability-limited and are stored refrigerated, with the lyophilized powders held frozen for longer-term storage away from light. Analytical identity and purity for each are commonly established by reversed-phase HPLC and mass spectrometry. Thus the format comparison yields few practical differences — the meaningful contrasts lie in receptor-target breadth, chain length, and conjugate chemistry rather than in handling.